Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 45 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL. The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: a case–control study. Br J Clin Pharmacol 2017;83:2541-8. [Ref.ID 102115]
2. Cita con resumen
Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study. Pharmacoepidemiol Drug Saf 2017;26:1141-8. [Ref.ID 102084]
3.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Stolk LM, de Vries F, Ebbelaar C, de Boer A, Schalekamp T, Souverein P, ten Cate-Hoek A, Burden AM. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101480]
5.Enlace a cita original Cita con resumen
Yasmina A, de Boer A, Deneer VHM, Souverein PC, Klungel OH. Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. Br J Clin Pharmacol 2017;83:632-41. [Ref.ID 101464]
6.Enlace a cita original
Nielen JTH, de Vries F, Dagnelie PC, van den Bemt BJF, Emans PJ, Lalmohamed A, de Boer A, Boonen A. Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study. Br J Clin Pharmacol 2016;81:370-8. [Ref.ID 100098]
7.Tiene citas relacionadas Cita con resumen
Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret C, Van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, De Faire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, de Borst GJ, De Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsley JD, Chasman D, Ridker PM, Magglioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Forhage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hoogeveen A, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61. [Ref.ID 98804]
8. Cita con resumen
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: database analysis. PLOS Medicine 2013;10:1. [Ref.ID 95146]
9.Tiene citas relacionadas Cita con resumen
van den Hoek HL, Bos WJW, de Boer A, van de GArde EMW. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ 2011;343:1242. [Ref.ID 91958]
10.Tiene citas relacionadas Cita con resumen
de Boer A. When to publish measures of disproportionality derived from spontaneous reporting databases?. Br J Clin Pharmacol 2011;72:909-11. [Ref.ID 91874]
11. Cita con resumen
Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol 2008;37:1142-7. [Ref.ID 84293]
12. Cita con resumen
Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BHCH, Leufkens HGM, de Boer A. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004;57:1223-31. [Ref.ID 84289]
13. Cita con resumen
Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Instrumental variables: application and limitations. Epidemiology 2006;17:260-7. [Ref.ID 84287]
14. Cita con resumen
Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008;168:180-5. [Ref.ID 82091]
15. Cita con resumen
Martens EP, de Boer A, Pestman WR, Belitser SV, Stricker BHCH, Klungel OH. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiol Drug Saf 2008;17:1-8. [Ref.ID 82050]
16.
Gumbs PD, Verschuren WM, Souverein PC, Mantel-Teeuwisse AK, de Wit GA, de Boer A, Klungel OH. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007;64:680-5. [Ref.ID 81387]
17.
Shalekamp T, van Geest-Daalderop JHH, Kramer MHH, van Holten-Verzantvoort ATM, de Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol 2007;63:335-43. [Ref.ID 79817]
18. Cita con resumen
Florentino SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HGM. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiol Drug Saf 2005;14:437-41. [Ref.ID 74369]
19. Cita con resumen
Mantel-Teewisse AK, Klungel OH, Schalekamp T, Verschuren WMM, Porsius AJ, de Boer A. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol 2005;60:83-9. [Ref.ID 74238]
20. Cita con resumen
Schelleman H, Stricker BHCH, de Boer A, Kroon AA, Verschuren MWM, Van Duijn CM, Psaty B M, Klungel OH. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004;64:1801-16. [Ref.ID 72776]
Seleccionar todas
 
 1 a 20 de 45 siguiente >>